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ABSTRACT
The type 2 diabetes mellitus epidemic threatens
public healthcare systems worldwide. Efforts to
prevent chronic complications of diabetes and
reduce their associated mortality have been
ineffective. Hence, early prevention of type 2
diabetes mellitus and cardiovascular disease
needs to be prioritized. This strategy, however,
must be centered not on an approach based on
hyperglycemia but on early pathophysiologic
mechanisms, such as insulin resistance. Non-
alcoholic fatty liver disease, androgenic alope-
cia, acanthosis nigricans, and polycystic ovarian
syndrome are all well-accepted early clinical
manifestations of insulin resistance that repre-
sent, in themselves, a risk for further develop-
ment of type 2 diabetes and that appear years
before hyperglycemia. Therefore, focusing
efforts on detecting and rigorously treating
patients with early clinical expression of insulin
resistance (insulin resistance clinical syndrome)
is probably the course of action that needs to be
taken to counterbalance the type 2 diabetes
mellitus epidemic.
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CLINICAL VIGNETTE
Today, a very common clinical scenario is a
17-year-old female with a family history of type
2 diabetes mellitus (T2DM) and hypertension in
her mother and two first-degree relatives. Three
years ago she was diagnosed with polycystic
ovarian syndrome (PCOS). She is overweight
with her body weight increasing 10 kg in the
last 2 years. Additionally, she has acanthosis
nigricans (AN) in the axillae and knuckles.
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Blood tests were unremarkable with a fasting
plasma glucose value of 82 mg/dl and an HbA1c
of 5.0%.
The first question of this clinical vignette is:
does this young woman have T2DM? The answer
is, of course, no. The second question is: does she
have insulin resistance (IR) with compensatory
hyperinsulinemia? The answer is yes. Currently,
however, the approach endorses a delay of one
to two decades to establish a diagnosis of T2DM.
Based on this everyday clinical case and the
predictable medical actions recommended for
the patient, the next question is: do we really
understand which is the initial true time to act
against T2DM? Should it be with clinical
expression of IR or hyperglycemia?
INTRODUCTION
Previous projections of T2DM prevalence have
been exceeded, with a current worldwide preva-
lence of more than 435 million patients [1]. The
socioeconomic implications of this epidemic
threaten worldwide public health systems, and
epidemiologic statistics of T2DM/obesity are
familiar to all clinicians. In fact, there has been a
100 million increment in T2DM cases in the last
10 years and an annual death rate of 1.5 million
[2]. Three out of four patients with T2DM are
economically active and more than 30% of the
global economic burden estimated for T2DM is
due to indirect expenses with mortality as the
main associated cause [3]. The current projections
are of catastrophic socioeconomic consequences
and require an immediate call for action. The
T2DM epidemic requires a different medical
approach. Efforts to prevent major macrovascular
complications and reduce their mortality have
been ineffective [4]. Antidiabetic medications
that have shown evidence of macrovascular risk
reduction have beenstudiedonly inveryhigh-risk
cardiovascular patients with T2DM, and, unfor-
tunately, these drugs are not easily available for
many patients, particularly in countries with a
very high incidence of T2DM, such as in devel-
oping countries [5]. As a consequence, the main
emphasis must focus on very early prevention of
T2DM and cardiovascular disease (CVD). This
strategy, however, must be centered not on the
development of hyperglycemia but on the disor-
ders occurring as a result of earlier pathophysio-
logical mechanisms, such as IR. Its manifestations
are tissue-specific signs that arise as the metabolic
burden worsens, some even before the develop-
ment of weight gain or obesity [6–10]. Despite the
absence of consensus in the diagnosis and man-
agement of IR, there is no question that T2DM,
hypertension, obesity, non-alcoholic fatty liver
disease (NAFLD), androgenetic alopecia, and AN
are well-recognized clinical expressions of IR,
particularly when they occur as a cluster and are
associated with a family history of the same.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
EARLY CLINICAL EXPRESSIONS
OF INSULIN RESISTANCE
AN, classically described in the neck, axillae, and
elbows of patients with obesity, has been recently
reported as an early and straightforward marker of
IR in young patients even with a normal BMI,
mainly in an ignored site such as the knuckles. It
has potential value as a useful tool for screening
patients with a high-metabolic risk in early stages
of the disease [6]. Patients with PCOS have a
higher risk for developing gestational diabetes
(OR = 2.1) and T2DM (OR = 8.8) and a higher
prevalence ofT2DM.Furthermore, when added to
AN, the prevalence of T2DM increases [7, 8]. Early
androgenetic alopecia has been suggested as a
clinical marker of IR, as well as presenting an
increased CVD risk [9]. NAFLD has been associ-
ated with IR and is an early detectable marker of
metabolic disease. It is found most frequently in
women with gestational diabetes mellitus.
Patients with NAFLD present a three- to fourfold
increased risk of developing T2DM [10].
ACT EARLIER—INSULIN
RESISTANCE CLINICAL SYNDROME
We recommend a T2DM approach not centered
on hyperglycemia but on strict management of
well-accepted IR clinical expressions.
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Furthermore, we could go a step further and
develop an easy and clear name to identify
clinical expressions of IR, such as IR clinical
syndrome. Therapy should be as strict as pro-
posed today once postprandial or fasting
hyperglycemia occurs. Under this perspective,
the main disorder to start therapy must be IR
clinical expressions (e.g., AN, androgenic
alopecia, PCOS). As soon as they appear, instead
of delaying therapy until the diagnosis of
T2DM, obesity, hypertension, dyslipidemia, or
CVD, all these individuals should undergo an
intensive aerobic and anaerobic exercise pro-
gram, a weight control low-calorie diet, and
likely for some metformin therapy (i.e., high-
risk patients with other comorbidities) under
close surveillance.
Treating only an elevated IR laboratory index
couldbe imprecise and leadto the other sideof the
spectrum, treating surrogate markers rather than
patients, a common practice nowadays that
diminishes resources and diverts attention from
those who could reallybenefit the most. However,
when several IR clinical manifestations are taken
into account, it is difficult to ignore that these are
patients who will develop obesity, metabolic
syndrome, T2DM, and CVD in the medium term.
Our lack of a strong action in this scenario is
unreasonable and enhances epidemic growth.
CONCLUSION
The game is set, the stakesare high, and the call for
action is clear. Ona global scale, direct investment
in diabetes prevention may reduce the economic
burden of the disease. In day-to-day clinical
practice, augmenting quality of life and life
expectancy should be the main goals for young
patients with a high metabolic risk. Therefore,
when facing a patient with early clinical signs of
IR, it is our responsibility to strongly and closely
intervene as soon as possible.
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